Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Lintzeris

Showing results (121-130 of 196) with videos related to

Pageof 20
Sort By:
Journal of Cannabis Research|August 16, 2025
Clinicians' attitudes and knowledge of medicinal cannabis in opioid dependence treatment clinics in New South Wales, AustraliaLaila Parvaresh, Llewellyn Mills, Jaleh Gholami, et al.
Psychopharmacology|May 3, 2019
Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognitionThomas R Arkell, Nicholas Lintzeris, Richard C Kevin, et al.
Drug and Alcohol Review|October 9, 2024
Integration of a facilitated access pathway for contraception into alcohol and other drug treatment services: A cohort study comparing metropolitan and regional settingsKelly A McNamara, Bridin Murnion, Nicholas Lintzeris, et al.
Drug and Alcohol Review|March 5, 2020
Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependenceLlewellyn Mills, Nicholas Lintzeris, Raimondo Bruno, et al.
Psychopharmacology|June 2, 2014
Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient settingJennifer Johnston, Nicholas Lintzeris, David J Allsop, et al.
Drug and Alcohol Review|February 24, 2018
Does training people to administer take-home naloxone increase their knowledge? Evidence from Australian programsPaul M Dietze, Bridget Draper, Anna Olsen, et al.
Drug and Alcohol Review|June 30, 2021
Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questionsKristie Mammen, Llewellyn Mills, Rachel M Deacon, et al.
The Medical Journal of Australia|August 4, 2009
Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulationLouisa Degenhardt, Briony K Larance, James R Bell, et al.
Drug and Alcohol Dependence|June 25, 2003
Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductionsCourtney L Breen, Simon J Harris, Nicholas Lintzeris, et al.
Drug and Alcohol Dependence|August 27, 2021
Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in AustraliaAnthony Barnett, Michael Savic, Nicholas Lintzeris, et al.
Pageof 20

Showing results (121-130 of 196) with videos related to

Sort By:
Pageof 20
Journal of Cannabis Research|August 16, 2025
Clinicians' attitudes and knowledge of medicinal cannabis in opioid dependence treatment clinics in New South Wales, AustraliaLaila Parvaresh, Llewellyn Mills, Jaleh Gholami, et al.
Psychopharmacology|May 3, 2019
Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognitionThomas R Arkell, Nicholas Lintzeris, Richard C Kevin, et al.
Drug and Alcohol Review|October 9, 2024
Integration of a facilitated access pathway for contraception into alcohol and other drug treatment services: A cohort study comparing metropolitan and regional settingsKelly A McNamara, Bridin Murnion, Nicholas Lintzeris, et al.
Drug and Alcohol Review|March 5, 2020
Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependenceLlewellyn Mills, Nicholas Lintzeris, Raimondo Bruno, et al.
Psychopharmacology|June 2, 2014
Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient settingJennifer Johnston, Nicholas Lintzeris, David J Allsop, et al.
Drug and Alcohol Review|February 24, 2018
Does training people to administer take-home naloxone increase their knowledge? Evidence from Australian programsPaul M Dietze, Bridget Draper, Anna Olsen, et al.
Drug and Alcohol Review|June 30, 2021
Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questionsKristie Mammen, Llewellyn Mills, Rachel M Deacon, et al.
The Medical Journal of Australia|August 4, 2009
Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulationLouisa Degenhardt, Briony K Larance, James R Bell, et al.
Drug and Alcohol Dependence|June 25, 2003
Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductionsCourtney L Breen, Simon J Harris, Nicholas Lintzeris, et al.
Drug and Alcohol Dependence|August 27, 2021
Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in AustraliaAnthony Barnett, Michael Savic, Nicholas Lintzeris, et al.
Pageof 20